AKBLF
Price
$28.95
Change
-$1.49 (-4.89%)
Updated
Jul 29 closing price
Capitalization
7.03B
CRDF
Price
$2.17
Change
+$0.04 (+1.88%)
Updated
Sep 5 closing price
Capitalization
144.36M
53 days until earnings call
Interact to see
Advertisement

AKBLF vs CRDF

Header iconAKBLF vs CRDF Comparison
Open Charts AKBLF vs CRDFBanner chart's image
Alk Abello AS
Price$28.95
Change-$1.49 (-4.89%)
Volume$1
Capitalization7.03B
Cardiff Oncology
Price$2.17
Change+$0.04 (+1.88%)
Volume$1.29M
Capitalization144.36M
AKBLF vs CRDF Comparison Chart in %
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. CRDF commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Hold and CRDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (AKBLF: $28.95 vs. CRDF: $2.17)
Brand notoriety: AKBLF and CRDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 15% vs. CRDF: 63%
Market capitalization -- AKBLF: $7.03B vs. CRDF: $144.36M
AKBLF [@Biotechnology] is valued at $7.03B. CRDF’s [@Biotechnology] market capitalization is $144.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileCRDF’s FA Score has 0 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • CRDF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBLF is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 2 TA indicator(s) are bullish while CRDF’s TA Score has 5 bullish TA indicator(s).

  • AKBLF’s TA Score: 2 bullish, 3 bearish.
  • CRDF’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than AKBLF.

Price Growth

AKBLF (@Biotechnology) experienced а 0.00% price change this week, while CRDF (@Biotechnology) price change was +3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBLF($7.03B) has a higher market cap than CRDF($144M). AKBLF YTD gains are higher at: 29.530 vs. CRDF (-50.000). AKBLF has higher annual earnings (EBITDA): 1.55B vs. CRDF (-53.95M). AKBLF has more cash in the bank: 517M vs. CRDF (71M). CRDF has less debt than AKBLF: CRDF (1.19M) vs AKBLF (800M). AKBLF has higher revenues than CRDF: AKBLF (5.71B) vs CRDF (545K).
AKBLFCRDFAKBLF / CRDF
Capitalization7.03B144M4,881%
EBITDA1.55B-53.95M-2,877%
Gain YTD29.530-50.000-59%
P/E Ratio41.37N/A-
Revenue5.71B545K1,047,339%
Total Cash517M71M728%
Total Debt800M1.19M67,511%
FUNDAMENTALS RATINGS
AKBLF vs CRDF: Fundamental Ratings
AKBLF
CRDF
OUTLOOK RATING
1..100
5054
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
4999
PRICE GROWTH RATING
1..100
4889
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (57) in the null industry is in the same range as AKBLF (80). This means that CRDF’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's Profit vs Risk Rating (46) in the null industry is somewhat better than the same rating for CRDF (100). This means that AKBLF’s stock grew somewhat faster than CRDF’s over the last 12 months.

AKBLF's SMR Rating (49) in the null industry is somewhat better than the same rating for CRDF (99). This means that AKBLF’s stock grew somewhat faster than CRDF’s over the last 12 months.

AKBLF's Price Growth Rating (48) in the null industry is somewhat better than the same rating for CRDF (89). This means that AKBLF’s stock grew somewhat faster than CRDF’s over the last 12 months.

AKBLF's P/E Growth Rating (78) in the null industry is in the same range as CRDF (100). This means that AKBLF’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFCRDF
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
20%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
39%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
35%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
36%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
N/A
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
21%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EMLC25.330.16
+0.64%
VanEck JPMorgan EMLcl Ccy Bd ETF
PSTP34.34-0.02
-0.06%
Innovator Power Buffer Step-Up Stgy ETF
PSCF59.24-0.09
-0.16%
Invesco S&P SmallCap Financials ETF
SPMC17.82-0.06
-0.34%
Sound Point Meridian Capital, Inc.
KBWP121.32-2.18
-1.77%
Invesco KBW Property & Casualty Ins ETF

AKBLF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBLF has been loosely correlated with CRDF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBLF jumps, then CRDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
CRDF - AKBLF
37%
Loosely correlated
+1.88%
MSCLF - AKBLF
28%
Poorly correlated
+2.85%
NGNE - AKBLF
25%
Poorly correlated
+1.73%
ADIL - AKBLF
25%
Poorly correlated
+0.61%
URGN - AKBLF
23%
Poorly correlated
+0.43%
More

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with QURE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+1.88%
QURE - CRDF
42%
Loosely correlated
+1.24%
NAMS - CRDF
42%
Loosely correlated
+5.22%
MRVI - CRDF
41%
Loosely correlated
+6.36%
AKBLF - CRDF
37%
Loosely correlated
N/A
NRIX - CRDF
37%
Loosely correlated
+8.66%
More